Sign In
Buy SNY
$43.98
-0.680 (-1.52%)
At Close: Jul 20, 2026
Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS®
08:00am, Wednesday, 10'th Sep 2025
Mandy Moore joins Elaine Welteroth, Gaby Dalkin, Katya Echazarreta, and Shawn Johnson East to share their personal respiratory syncytial virus (RSV) stories and why they chose BEYFORTUS to help prote
Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
01:00am, Wednesday, 10'th Sep 2025
Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
Sanofi (SNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
04:40pm, Tuesday, 09'th Sep 2025
Sanofi (NASDAQ:SNY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:05 PM EDT Company Participants Paul Hudson - CEO & Director Conference Call Participants Sarita Kapila
Sanofi market value tanks following weak results on eczema drug trials
02:56pm, Thursday, 04'th Sep 2025
Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after late-stage trial data for its experimental inflammatory disease drug amlitelimab
Why Is Sanofi Stock Falling Thursday?
02:36pm, Thursday, 04'th Sep 2025
On Thursday, Sanofi SA SNY stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fre
SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study
11:51am, Thursday, 04'th Sep 2025
Sanofi shares fall despite phase III success for eczema drug candidate, amlitelimab, showing strong efficacy and safety in patients.
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors
09:21am, Thursday, 04'th Sep 2025
French drugmaker Sanofi SA SNY stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expecta
Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'
09:07am, Thursday, 04'th Sep 2025
Sanofi stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent.
Sanofi Shares Sink as Experimental Drug Results Disappoint
04:43am, Thursday, 04'th Sep 2025
Sanofi shares plunged at the market open Thursday as results from a late-stage trial of its experimental drug to treat skin conditions disappointed investors.
Sanofi shares sink over 9% on weak trial results for experimental inflammation drug
04:01am, Thursday, 04'th Sep 2025
Shares in French drugmaker Sanofi fell more than 9% on Thursday after late-stage trial data for its experimental inflammatory disease drug amlitelimab fell short of Wall Street expectations.
Sanofi's Eczema Drug Candidate Hits Main Goals in Late-Stage Trial
01:46am, Thursday, 04'th Sep 2025
Amlitelimab showed efficacy in skin clearance and disease severity compared to placebo in a phase 3 study with adolescent and adults with atopic dermatitis.
Sanofi's amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
Global drugmakers rush to boost US presence as tariff threat looms
02:09pm, Wednesday, 03'rd Sep 2025
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Thermo Fisher Scientific Completes Acquisition of Sanofi's Ridgefield, New Jersey Site
08:15am, Tuesday, 02'nd Sep 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced the completion of its acquisition of Sanofi's state-of-the-art sterile f
Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia
01:31pm, Monday, 01'st Sep 2025
SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.
